Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal

Taiho Pharmaceutical and Cullinan Therapeutics achieved positive phase 3 trial results for their drug zipalertinib in first-line treatment of EGFR exon 20 insertion mutation non-small cell lung cancer, positioning them to compete with Johnson & Johnson's established lung cancer treatments. An FDA decision on zipalertinib’s second-line use is expected by February 2027, with potential $100 million payment to Cullinan on first-line approval and Taiho leading US sales efforts.

This Wire brief sits within Fusion42's coverage of Biotech.